Advertisement

Long-term breast cancer risk following ovarian stimulation in young egg donors: a call for follow-up, research and informed consent

      Abstract

      In the USA and other countries, oocyte donation is gaining increasing importance. Although sufficient data exist on procedure-associated short-term risks for oocyte donors, such as ovarian hyperstimulation syndrome, long-term follow-up studies of egg donors are lacking and their health risks are unknown. The lack of information may be misleadingly interpreted as lack of risk. Long-term hormone replacement therapy is recognized as a risk factor for breast cancer; the breast cancer risk of ovarian stimulation for egg donors is unknown but is a possibility. This commentary describes five individual cases of egg donors who developed breast cancer (four out of five women in their 30s) despite negative genetic testing results. Additionally, we summarize available studies of breast cancer in infertile women who experienced IVF. We emphasize the need to create egg donor registries that will facilitate long-term studies on egg donors. Until this information is available, we call for more realistic explanations to egg donors about the lack of knowledge of long-term risks as well as more transparent informed consent documents.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Reproductive BioMedicine Online
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ahuja K.K.
        • Simons E.G.
        Cancer of the colon in an egg donor: policy repercussions for donor recruitment.
        Hum. Reprod. 1998; 13: 227-231
        • American Cancer Society
        Global Cancer Facts & Figures.
        3rd ed. 2015: 35
        • Antoniou A.C.
        • Cunningham A.P.
        • Peto J.
        • Evans D.G.
        • Lalloo F.
        • Narod S.A.
        • Risch H.A.
        • Eyfjord J.E.
        • Hopper J.L.
        • Southey M.C.
        • Olsson H.
        • Johannsson O.
        • Borg A.
        • Pasini B.
        • Radice P.
        • Manoukian S.
        • Eccles D.M.
        • Tang N.
        • Olah E.
        • Anton-Culver H.
        • Warner E.
        • Lubinski J.
        • Gronwald J.
        • Gorski B.
        • Tryggvadottir L.
        • Syrjakoski K.
        • Kallioniemi O.P.
        • Eerola H.
        • Nevanlinna H.
        • Pharoah P.D.
        • Easton D.F.
        The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
        Br. J. Cancer. 2008; 98: 1457-1466
        • Beral V.
        • Million Women Study Collaborators
        Breast cancer and hormone-replacement therapy in the Million Women Study.
        Lancet. 2003; 362: 419-427
        • Breastcancer.org
        U.S. breast cancer statistics.
        (Accessed 3 August 2016)
        • Brinton L.
        Long-term effects of ovulation-stimulating drugs on cancer risk.
        Reprod. Biomed. Online. 2007; 15: 38-44
        • Brinton L.A.
        • Scoccia B.
        • Moghissi K.S.
        • Westhoff C.L.
        • Althuis M.D.
        • Mabie J.E.
        Breast cancer risk association with ovulation-stimulating drugs.
        Hum. Reprod. 2004; 19: 2005-2013
        • Brinton L.A.
        • Westhoff C.L.
        • Scoccia B.
        • Lamb E.J.
        • Althuis M.D.
        • Mabie J.E.
        • Moghissi K.S.
        Causes of infertility as predictors of subsequent cancer risk.
        Epidemiology. 2005; 16: 500-507
        • Brinton L.A.
        • Scoccia B.
        • Moghissi K.S.
        • Westhoff C.L.
        • Niwa S.
        • Ruggieri D.
        • Trabert B.
        • Lamb E.J.
        Long-term relationship of ovulation-stimulating drugs to breask cancer risk.
        Cancer Epidemiol. Biomarkers Prev. 2014; 23: 584-593
        • Endogenous Hormones and Breast Cancer Collaborative Group
        Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies.
        Lancet Oncol. 2013; 14: 1009-1019
      1. Giudice L. Santa E. Pool R. Assessing the Medical Risks of Human Oocyte donation for Stem Cell Research: Workshop Report. The National Academies Press, Washington, DC2007https://doi.org/10.17226/11832
      2. Howlader N. Noone A.M. Krapcho M. Neyman N. Aminou R. Waldron W. Altekruse S.F. Kosary C.L. Ruhl J. Tatalovich Z. Cho H. Mariotto A. Eisner M.P. Lewis D.R. Chen H.S. Feuer E.J. Cronin K.A. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD2012 (Accessed 23 October 2016)
        • Kawwass J.F.
        • Monsour M.
        • Crawford S.
        • Kissin D.M.
        • Session D.R.
        • Kulkarni A.D.
        Trends and outcomes for donor oocyte cycles in the United States 2000–2010.
        J. Am. Med. Assoc. 2013; 310: 2426-2434
        • Källén B.
        • Finnström O.
        • Lindam A.
        • Nilsson E.
        • Nygren K.G.
        • Olausson P.O.
        Malignancies among women who gave birth after in vitro fertilization.
        Hum. Reprod. 2011; 26: 253-258
        • Kristiansson P.
        • Bjor O.
        • Wramsby H.
        Tumour incidence in Swedish women who gave birth following IVF treatment.
        Hum. Reprod. 2007; 22: 421-426
        • Li L.L.
        • Zhou J.
        • Qian X.J.
        • Chen Y.D.
        Meta-analysis on the possible association between in vitro fertilization and cancer risk.
        Int. J. Gynecol. Cancer. 2012; 23: 16-24
        • Liberty G.
        • Hyman J.
        • Friedler S.
        • Anteby E.Y.
        • Margalioth E.J.
        High rates of abnormalities in hysterosalpingography in couples with male factor infertility.
        Clin. Exp. Obstet. Gynecol. 2014; 41: 415-418
        • National Public Radio
        Silicon valley companies add new benefit for women: egg-freezing.
        (October 14) (Accessed 2 February 2017)
        • Schattman G.L.
        Cryopreservation of oocytes.
        N. Engl. J. Med. 2015; 373: 1755-1760
        • Schneider J.P.
        Fatal colon cancer in a young egg donor: a physician mother's call for follow-up and research on the long-term risks of ovarian stimulation.
        Fertil. Steril. 2008; 90https://doi.org/10.1016/j.fertnstert.2007.12.074
        • Schneider J.P.
        Cryopreservation of oocytes. Letter to the Editor.
        N. Engl. J. Med. 2016; 374: 287-288
        • Sergentanis T.N.
        • Diamantaras A.
        • Perlepe C.
        • Kanavidis P.
        • Skalkidou A.
        • Petridou E.T.
        IVF and breast cancer: a systematic review and meta-analysis.
        Hum. Reprod. Update. 2014; 20: 106-123
        • Stewart L.M.
        • Holman C.D.
        • Hart R.
        • Bulsara M.K.
        • Preen D.B.
        • Finn J.C.
        In vitro fertilization and breast cancer: is there cause for concern?.
        Fertil. Steril. 2012; 98: 334-340
        • Time Magazine
        Time Magazine Company-paid egg freezing will be the great equalizer.
        (Oct 15) (Accessed 2 February 2017)
        • Van den Belt-Dusebout A.W.
        • Spaan M.
        • Lambalk C.B.
        • Kortman M.
        • Laven J.S.E.
        • van Santbrink E.J.P.
        • van der Westertaken L.A.
        • Cohlen B.J.
        • Braat D.D.M.
        • Smeenk J.M.J.
        • Land J.A.
        • Goddijn M.
        • vanGolde R.J.T.
        • van Rumste M.M.
        • Schats R.
        • Jozwlak K.
        • Hauptmann M.
        • Rookus M.S.A.
        • Burger C.W.
        • van Leeuwen F.E.
        Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer.
        JAMA. 2016; 316: 300-312
        • World Cancer Research Fund International
        Breast cancer statistics.
        (Accessed 5 December 2016)